EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Cerebrospinal fluid biomarkers in the Longitudinal Early‐onset Alzheimer's Disease Study

Jeffrey L Dage, Ani Eloyan, Maryanne Thangarajah, Dustin B Hammers, Anne M Fagan, Julia D Gray, Suzanne E Schindler, Casey Snoddy, Kelly N H Nudelman, Kelley M Faber, Tatiana Foroud, Paul Aisen und 39 weitere

Alzheimer's & Dementia · 2023

DOI: 10.1002/alz.13399 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2023. Verfasst von Jeffrey L Dage und 50 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, NIDCD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

One goal of the Longitudinal Early Onset Alzheimer's Disease Study (LEADS) is to define the fluid biomarker characteristics of early‐onset Alzheimer's disease (EOAD).

Methods

Cerebrospinal fluid (CSF) concentrations of Aβ1‐40, Aβ1‐42, total tau (tTau), pTau181, VILIP‐1, SNAP‐25, neurogranin (Ng), neurofilament light chain (NfL), and YKL‐40 were measured by immunoassay in 165 LEADS participants. The associations of biomarker concentrations with diagnostic group and standard cognitive tests were evaluated.

Results

Biomarkers were correlated with one another. Levels of CSF Aβ42/40, pTau181, tTau, SNAP‐25, and Ng in EOAD differed significantly from cognitively normal and early‐onset non‐AD dementia; NfL, YKL‐40, and VILIP‐1 did not. Across groups, all biomarkers except SNAP‐25 were correlated with cognition. Within the EOAD group, Aβ42/40, NfL, Ng, and SNAP‐25 were correlated with at least one cognitive measure.

Discussion

This study provides a comprehensive analysis of CSF biomarkers in sporadic EOAD that can inform EOAD clinical trial design.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseHumansChitinase-3-Like Protein 1Amyloid beta-Peptidestau ProteinsLongitudinal StudiesBiomarkersNeurogranin

Stichwörter der Autor:innen

Alzheimer's diseaseAβ42/40CSFNfLSNAP-25VILIP-1YKL-40amyloidastrogliosisbiomarkersdementianeurograninpTau181tTautau

Substanzen

Chitinase-3-Like Protein 1Amyloid beta-Peptidestau ProteinsBiomarkersNeurogranin

Autor:innen und Institutionen

  • Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Department of Biostatistics, Center for Statistical Sciences, Brown University, Providence, Rhode Island, USA.
  • Department of Neurology, Washington University in St. Louis, St. Louis, Missouri, USA.
  • Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA.
  • Medical & Scientific Relations Division, Alzheimer's Association, Chicago, Illinois, USA.

Förderung

  • NIA NIH HHS
  • NIDCD NIH HHS

Zitieren

APA

Dage, J. L., Eloyan, A., Thangarajah, M., Hammers, D. B., Fagan, A. M., Gray, J. D., Schindler, S. E., Snoddy, C., Nudelman, K. N. H., Faber, K. M., Foroud, T., Aisen, P., Griffin, P., Grinberg, L. T., Iaccarino, L., Kirby, K., Kramer, J., Koeppe, R., Kukull, W. A., …, & LEADS Consortium (2023). Cerebrospinal fluid biomarkers in the Longitudinal Early‐onset Alzheimer's Disease Study. Alzheimer's & Dementia. https://doi.org/10.1002/alz.13399

Vancouver

Dage JL, Eloyan A, Thangarajah M, Hammers DB, Fagan AM, Gray JD, et al. Cerebrospinal fluid biomarkers in the Longitudinal Early‐onset Alzheimer's Disease Study. Alzheimer's & Dementia. 2023. doi:10.1002/alz.13399

BibTeX
@article{Dage2023,
  author = {Dage, Jeffrey L and Eloyan, Ani and Thangarajah, Maryanne and Hammers, Dustin B and Fagan, Anne M and Gray, Julia D and Schindler, Suzanne E and Snoddy, Casey and Nudelman, Kelly N H and Faber, Kelley M and Foroud, Tatiana and Aisen, Paul and Griffin, Percy and Grinberg, Lea T and Iaccarino, Leonardo and Kirby, Kala and Kramer, Joel and Koeppe, Robert and Kukull, Walter A and La Joie, Renaud and Mundada, Nidhi S and Murray, Melissa E and Rumbaugh, Malia and Soleimani-Meigooni, David N and Toga, Arthur W and Touroutoglou, Alexandra and Vemuri, Prashanthi and Atri, Alireza and Beckett, Laurel A and Day, Gregory S and Graff-Radford, Neill R and Duara, Ranjan and Honig, Lawrence S and Jones, David T and Masdeu, Joseph C and Mendez, Mario F and Musiek, Erik and Onyike, Chiadi U and Riddle, Meghan and Rogalski, Emily and Salloway, Stephen and Sha, Sharon J and Turner, Raymond S and Wingo, Thomas S and Wolk, David A and Womack, Kyle B and Carrillo, Maria C and Dickerson, Bradford C and Rabinovici, Gil D and Apostolova, Liana G and LEADS Consortium, LEADS Consortium},
  title = {Cerebrospinal fluid biomarkers in the Longitudinal Early‐onset Alzheimer's Disease Study},
  journal = {Alzheimer's & Dementia},
  year = {2023},
  doi = {10.1002/alz.13399}
}
Kostenlos starten →